3025452-07-4
Chemical Structure
Vepdegestrant-d5
Synonym(s): ARV-471-d5
- CAS No.: 3025452-07-4
- Formula:C45H44D5N5O4
- Molecular Weight:728.93
InChIKey: TZZDVPMABRWKIZ-SSBBKDJISA-N
SMILES: O=C1NC([C@@H](N(C2=O)CC3=C2C=CC(N(CC4)CCN4CC(CC5)CCN5C(C=C6)=CC=C6[C@H]7[C@@H](C8=C([2H])C([2H])=C([2H])C([2H])=C8[2H])CCC9=C7C=CC(O)=C9)=C3)CC1)=O
Biological Activity: Vepdegestrant-d5 (ARV-471-d5) is the deuterium labeled Vepdegestrant (HY-138642). Vepdegestrant (ARV-471) is an orally active PROTAC estrogen receptor degrader against breast cancer. Vepdegestrant is a hetero-bifunctional molecule that facilitates the interactions between estrogen receptor alpha and an intracellular E3 ligase complex. Vepdegestrant leads to the ubiquitylation and subsequent degradation of estrogen receptors via the proteasome. Vepdegestrant robustly degrades ER in ER-positive breast cancer cell lines with a DC50 of about 2 nM[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Vepdegestrant-d5 | Vepdegestrant-d5 (ARV-471-d5) is the deuterium labeled Vepdegestrant (HY-138642). Vepdegestrant (ARV-471) is an orally active PROTAC estrogen receptor degrader against breast cancer. Vepdegestrant is a hetero-bifunctional molecule that facilitates the interactions between estrogen receptor alpha and an intracellular E3 ligase complex. Vepdegestrant leads to the ubiquitylation and subsequent degradation of estrogen receptors via the proteasome. Vepdegestrant robustly degrades ER in ER-positive breast cancer cell lines with a DC50 of about 2 nM. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Vepdegestrant | 99.20% | Vepdegestrant (ARV-471) is an orally active PROTAC estrogen receptor degrader against breast cancer. Vepdegestrant is a hetero-bifunctional molecule that facilitates the interactions between estrogen receptor alpha and an intracellular E3 ligase complex. Vepdegestrant leads to the ubiquitylation and subsequent degradation of estrogen receptors via the proteasome. Vepdegestrant robustly degrades ER in ER-positive breast cancer cell lines with a half-maximal degradation concentration (DC50) of about 2 nM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Keywords
